Chronic Idiopathic Constipation (CIC) Treatment Market: By Drug Class (Emollients, Laxatives, Bulk-forming agents, Chloride channel activators, Osmotic products, Others), By Route of Administration (Oral, Parenteral), By Distribution Mode (Prescription mode, Over-the-counter drugs), By Distribution Channel (Hospital pharmacies, Retail pharmacies, Online pharmacies, Drug Stores) and Geography

Chronic Idiopathic Constipation (CIC) Treatment Market size was estimated at USD 8.2 billion in 2023 and is poised to grow at a CAGR of 7.2% from 2024-2030. Chronic idiopathic constipation is a functional gastrointestinal disorder that leads to difficulty in defecating. It is a more chronic or severe condition and the symptoms of the disease include bloating, abdominal discomfort, hard stool, incomplete evacuation, gastric pain, and strain during the bowel movement. It is an idiopathic condition due to the causes of the disease are unclear, however, it may be due to psychological, neurological, and psychosomatic conditions.

Chronic idiopathic constipation is majorly caused in adults or geriatric people. Diagnosis of CIC is difficult due to the lack of physiological causes and physicians look for symptoms like weight, blood in stool, and low blood count among others. The chronic idiopathic constipation Treatment market is growing at a significant CAGR owing to recent product approvals and competitor's focus on the development of newer drugs for CIC treatment. Moreover, an increase in the prevalence of chronic idiopathic constipation cases is also expected to propel the market revenue over the forecast period. Acquisitions and mergers, product approvals, and product launches are the key strategies adopted by the companies to increase their revenue share in the market. For instance, In January 2017, the FDA approved Tulane manufactured by Synergy Pharmaceuticals used in the treatment of chronic idiopathic constipation.